CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst

Just one day after the ascendant biotech CRISPR Therapeutics (CRSP -1.62%) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the stock to $112, suggesting that it could rise by 32% from its current price. The company is in the process of commercializing its first medicine, a gene therapy called Casgevy that it developed to treat beta thalassemia and sickle cell disease (SCD) as part of a collaboration with Vertex Pharmaceuticals. Casgevy was ...